NovoCure Limited (NASDAQ:NVCR) Shares Purchased by C WorldWide Group Holding A S

C WorldWide Group Holding A S increased its holdings in shares of NovoCure Limited (NASDAQ:NVCR) by 19.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 621,784 shares of the medical equipment provider’s stock after acquiring an additional 100,000 shares during the period. C WorldWide Group Holding A S’s holdings in NovoCure were worth $18,529,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Blue Trust Inc. grew its position in shares of NovoCure by 70.7% during the 4th quarter. Blue Trust Inc. now owns 1,886 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 781 shares during the period. Brooklyn Investment Group acquired a new stake in shares of NovoCure during the 3rd quarter valued at about $45,000. Versant Capital Management Inc boosted its holdings in NovoCure by 35.8% in the 4th quarter. Versant Capital Management Inc now owns 3,341 shares of the medical equipment provider’s stock worth $100,000 after buying an additional 880 shares during the last quarter. Venturi Wealth Management LLC boosted its holdings in NovoCure by 58.5% in the 3rd quarter. Venturi Wealth Management LLC now owns 3,669 shares of the medical equipment provider’s stock worth $57,000 after buying an additional 1,354 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in NovoCure by 21.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,914 shares of the medical equipment provider’s stock worth $61,000 after buying an additional 701 shares during the last quarter. 84.61% of the stock is currently owned by institutional investors and hedge funds.

NovoCure Trading Up 2.0 %

NVCR opened at $22.09 on Monday. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.49 and a quick ratio of 1.44. The company’s 50 day simple moving average is $26.65 and its two-hundred day simple moving average is $21.39. NovoCure Limited has a 1-year low of $11.70 and a 1-year high of $34.13. The firm has a market capitalization of $2.39 billion, a price-to-earnings ratio of -15.78 and a beta of 0.62.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $38.00 price objective on shares of NovoCure in a report on Tuesday, January 14th. Evercore ISI upgraded NovoCure from an “in-line” rating to an “outperform” rating and lifted their price objective for the stock from $18.00 to $30.00 in a report on Monday, December 2nd. Wedbush reiterated a “neutral” rating and issued a $29.00 price objective on shares of NovoCure in a report on Monday, January 13th. Finally, Piper Sandler lifted their price objective on NovoCure from $28.00 to $42.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.67.

NovoCure Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.